Bruce Armitage, PhD
Bruce Armitage is Co-Founder and Co-Director of the Center for Nucleic Acids Science and Technology (CNAST), a Professor of Chemistry at Carnegie Mellon University, and Co-Founder of PNA Innovations, Inc.
Bruce received his BS in Chemistry from the University of Rochester in 1988, and spent two summers working in labs at the Eastman Kodak Company before obtaining his PhD from the University of Arizona studying electron and energy transfer within lipid bilayers. Dr. Armitage then served as an NIH post-doctoral Fellow at the University of Illinois and Georgia Tech, as well as an NSF International Research Fellow at the University of Copenhagen, designing new DNA photo cleavage agents. His current lab utilizes biomolecular recognition in the study of nucleic acid biology and chemistry, as well as supramolecular photochemistry.
In 2011, Dr. Armitage co-founded PNA Innovations, Inc, which is commercializing gammaPNA technology under exclusive license from Carnegie Mellon University, with financial support from private investors and SBIR funding from the National Institutes of Health. Bruce has been awarded with the William and Frances Ryan Award for Meritorious Teaching and the CMU Chapter National Society of Collegiate Scholars “Outstanding Professor” Award; he has also served as President of the Inter-American Photochemical Society and Co-Chair of the Gordon Research Conference on Photochemistry.
Markus Covert, PhD
Markus Covert is a Professor of Bioengineering at Stanford University, recently leading simulations of the “first organism in software”. His whole-cell models of biological processes in higher organisms have been featured in Cell, Nature, and The New York Times. Dr. Covert received a BS in chemical engineering from Brigham Young University, before receiving his PhD in bioengineering and bioinformatics from the University of California, San Diego for his investigations into the interaction between microbial metabolism and transcriptional regulation. He was awarded a post-doctoral fellowship from the Damon Runyon Cancer Research Foundation to study mammalian cell signaling at the California Institute of Technology before coming to Stanford. He was recently honored with the NIH Director’s Pioneer Award in 2009, as well as the Paul G. Allen Distinguished Investigators Award in 2013.
Lawrence Pileggi, PhD
Lawrence Pileggi is the Tanoto Professor of Electrical and Computer Engineering at Carnegie Mellon University, and has previously held positions at Westinghouse Research and Development and the University of Texas at Austin. He received his PhD in Electrical and Computer Engineering from Carnegie Mellon University in 1989. He has consulted for various semiconductor and EDA companies, and was co-founder of Fabbrix Inc. (acquired by PDF Solutions) and Extreme DA (acquired by Synopsys). His research interests include all aspects of integrated circuit design and design methodologies. He has received several awards, including Westinghouse Corporation’s highest engineering achievement award, the SRC Aristotle Award in 2008, the 2010 IEEE Circuits and Systems Society Mac Van Valkenburg Award, the ACM/IEEE A. Richard Newton Technical Impact Award in Electronic Design Automation in 2011, and the Carnegie Institute of Technology B.R. Teare Teaching Award for 2013. He is a co-author of “Electronic Circuit and System Simulation Methods,” McGraw-Hill, 1995 and “IC Interconnect Analysis,” Kluwer, 2002. He has published over 300 conference and journal papers, and holds 31 U.S. patents. He is a fellow of IEEE.
David Pompliano, PhD
David L. Pompliano, PhD is an Entrepreneur-in-Residence at Third Rock Ventures. He is also Principal and Owner at Sanderling Consulting LLC, where he assists investors, companies and philanthropies in setting drug discovery strategy, in executing the operations of preclinical discovery and development, and in evaluating pharmaceutical assets. He has over 20 years of experience in the biopharmaceutical industry, most recently as CEO of BioLeap, a discovery stage platform technology company. Before that, he was a senior pharmaceutical executive at GlaxoSmithKline and Merck, where he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and four registered anti-infective (Altabax) and oncology (Tykerb, Votrient, Promacta) drugs. Pompliano earned BS and PhD degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and was an NIH Postdoctoral Fellow in Jeremy Knowles’ laboratory at Harvard University. He serves on the Scientific Advisory Boards for ActivX BioSciences, Advanced Plasma Therapies, and Emerald Therapeutics.
Steve Teig is President and CTO of Tabula, which was recognized in 2012 with an Edison Award, an American Business Gold Award, inclusion in MIT’s “TR50” list of the 50 most innovative companies worldwide, and as #3 in the Wall Street Journal’s “Next Big Thing” list of most promising venture-backed startup companies.
Prior to founding Tabula and inventing Tabula’s Spacetime 3-Dimensional Programmable Logic Architecture, Steve was CTO of Cadence (NSDQ:CDNS), which he joined through its acquisition of Simplex (NSDQ:SPLX), where he also served as CTO. Prior to Simplex, he co-founded and served as CTO of two successful biotechnology companies, CombiChem (NSDQ:CCHM, acquired by DuPont Pharmaceuticals) and BioCAD (acquired by Accelrys). At CombiChem, he invented and led the development of the technology with which CombiChem discovered pharmaceutical-lead compounds for 11 different therapeutic areas in only 5 years. At BioCAD, he designed Catalyst, which is still the leading software used worldwide for pharmaceutical discovery.
Steve also holds over 250 patents, and received his BSE in Electrical Engineering and Computer Science from Princeton University. In 2011, he was awarded the World Technology Award for IT hardware innovation.
Stephen Wolfram, PhD
Stephen Wolfram is creator of Mathematica and Wolfram|Alpha, author of A New Kind of Science, and president and CEO of Wolfram Research since its founding in 1987. Wolfram is deeply involved in development of the company’s technology, and personally oversees the functional design of the company’s core products, which are used by millions of people every day.
Born in London in 1959, Wolfram was educated at Eton, Oxford, and Caltech. He published his first scientific paper at age 15, and received his PhD in theoretical physics from Caltech by age 20. Wolfram’s early scientific work in high-energy physics, quantum field theory, and cosmology included several now-classic results. He started using computers in 1973, and rapidly became a leader in early scientific computing. He commercially released SMP – the first modern computer algebra system – in 1981, and became the youngest recipient of a MacArthur Fellowship that same year.
From 1981, Wolfram focused on leading an ambitious new direction in science: using computer experiments to make discoveries about understanding the origins of complexity in nature. As part of his groundbreaking work, Wolfram founded the first research center and first journal in the field, Complex Systems, in 1986. His discoveries led to a wide range of inventions and applications, including a new randomness generation system, a new approach to computational fluid dynamics, and the concept of computational irreducibility. After a highly successful career in academia — first at Caltech, then at the Institute for Advanced Study in Princeton, and finally as Professor of Physics, Mathematics, and Computer Science at the University of Illinois — Wolfram launched Wolfram Research, Inc.
Wolfram began development of Mathematica in late 1986. The first version was immediately hailed as a major advance in computing; as the popularity of Mathematica grew, Wolfram Research became established as a world leader in software, widely recognized for excellence in both technology and business. Currently at Version 9, Mathematica has become the standard software language and environment for technical, scientific, algorithmic computation and software development.
With Mathematica as a research tool, Wolfram made a number of major scientific discoveries, which led him to develop a fundamentally new conceptual framework he has since applied to foundational problems in physics, biology, computer science, mathematics, and several other fields. After more than ten years of highly concentrated work, Wolfram finally described his achievements in his widely-acclaimed best-seller, A New Kind of Science.
Wolfram next embarked on his most ambitious project to date: building a system that made as much of the world’s knowledge as possible computable and accessible to everyone. The release of Wolfram|Alpha in May 2009 was widely viewed as a landmark point in history, defining a new dimension for computation. Building on the deep technology stacks of Mathematica, Wolfram|Alpha, and the advances of A New Kind of Science, Wolfram is now developing products in several new important directions.